Cumulative effects of hypertriglyceridemia in HIV-infected patients switching from NNRTIs to PI-based antiretroviral therapy

J Infect Dev Ctries. 2022 Mar 31;16(3):528-536. doi: 10.3855/jidc.12519.


Introduction: The objective of this study was to investigate changes in serum lipids among HIV-infected patients switching from non-nucleoside-reverse transcriptase inhibitors (NNRTI) to protease inhibitor (PI)-based highly active antiretroviral therapy (HAART), and to determine if changes of lipid profiles impacted the monocyte subsets recovery.

Methodology: Fifty-seven subjects who switched from NNRTIs to PI-based HAART (NNRTIs to PI group) and fifty-five subjects who initially started with PI-based HAART (initial PI group) were recruited. According to their baseline triglyceride (TG) levels, the NNRTIs to PI and initial PI groups were further divided into non-hypertriglyceridemia and hypertriglyceridemia subgroups, respectively. The effects of PI-based HAART on lipid profiles and monocyte subsets were analyzed.

Results: At 48 weeks, the TG changes in the NNRTIs to PI group was higher than that of the initial PI group. The increases of serum TG levels in the initial PI non-hypertriglyceridemia group was greater than that of the NNRTIs to PI non-hypertriglyceridemia group. For the hypertriglyceridemia group at baseline, significant increment in TG levels were observed in the NNRTIs to PI hypertriglyceridemia group. The percentages of circulating CD14highCD16+ and CD14lowCD16+ subsets were elevated in the two groups. At 48 weeks, the proportion of CD14highCD16+ monocytes declined gradually, and the proportion of CD14lowCD16+ monocytes decreased independently of the TG level.

Conclusions: For non-hypertriglyceridemia individuals at baseline, PI-based regimens increased the TG level in the initial PI group. For the NNRTIs to PI hypertriglyceridemia group, PI-based regimens reinforced HAART-related hypertriglyceridemia.

Keywords: Non-nucleoside reverse transcriptase inhibitors; highly active antiretroviral therapy; hypertriglyceridemia; protease inhibitors.

MeSH terms

  • Anti-HIV Agents* / adverse effects
  • Anti-Retroviral Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active / adverse effects
  • HIV Infections* / complications
  • HIV Infections* / drug therapy
  • HIV Protease Inhibitors* / therapeutic use
  • Humans
  • Hypertriglyceridemia* / chemically induced
  • Hypertriglyceridemia* / drug therapy
  • Lipids / therapeutic use
  • Reverse Transcriptase Inhibitors / adverse effects


  • Anti-HIV Agents
  • Anti-Retroviral Agents
  • HIV Protease Inhibitors
  • Lipids
  • Reverse Transcriptase Inhibitors